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SUMMARY
Ergometrine was injected in rats intraperitoneally or intravenously and also 
directly into different parts of the brain. After peripheral injection the animals showed 
a characteristic crawling behaviour. This behaviour was reversed by apomorphine.
Following bilateral injection of ergometrine into the nucleus accumbens, the 
rats showed a biphasic response. After a period, during which sedation and ptosis 
predominated, there followed a strong and long-lasting locomotor stimulation, which 
started and finished in most cases rather abruptly. When the doses of ergometrine 
were lowered the locomotor activity remained at a constant high level, but the dura- 
tion was shorter. Bilateral injection of ergometrine into the caudate nucleus or into 
the septum had only little or no stimulant effect on locomotor activity.
The strong locomotor stimulation following injection of ergometrine into the 
nucleus accumbens was inhibited by low doses of haloperidol and pimozide given 
intraperitoneally.
Pretreatment with a-methyl-p-tyrosine had no influence on this motor activity.
Ergometrine injected unilaterally into the nucleus accumbens and into the 
caudate nucleus caused only a slight enhanced locomotor activity and turning to the 
contralateral side.
The possible mode of action of ergometrine is discussed.
INTRODUCTION
Ergometrine has been used widely in therapy as a uterus spasmogen since its 
pharmacological properties were described in detail by Brown and Sir Henry Dale5
* Present address: Department o f Physiology and Biochemistry, University of Southampton, South- 
am pton SO 9 5NH, Great Britain.
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in 1935. They also described a central stimulant action of ergometrine with the 
production of ‘sham rage’. A  similar effect was reported by Gaddum and Vogt13 
after the injection of 2 mg ergometrine into the lateral ventricle of conscious cats.
Recently ergometrine has been shown to be a potent antagonist of the inhibitory 
action of dopamine on neurones of the snail Helix aspersa23’26. The effect of dopamine 
on these Helix aspersa neurones appears to be mediated by true dopamine receptors25.
In the mammalian brain dopamine plays an essential role14. We have considered 
the possibility that some of the central actions of ergometrine in mammals could be 
brought about by an action on dopamine receptors. For this reason we decided to 
investigate some of the central actions of this compound in rats by intracerebral injec- 
tions. In this paper we report a strong locomotor stimulant action of ergometrine.
METHODS
Intraperitoneal and intravenous injections
Male Wistar rats were used, weighing 150-200 g, housed in groups of 3, with 
free access to food and water.
In some experiments groups of 4 rats, each subjected to drug treatment, were 
placed in a semicircular wooden cage with a glass front. The cage had a radius of 
40 cm and a height of 60 cm. In another similar cage 4 untreated or vehicle treated 
animals were placed for comparison. The behaviour of the animals was observed for 
up to 4 h  following the injection.
In  other experiments individual animals were placed in a motor activity cage 
(see under apparatus) and locomotor activity was recorded for up to 6 h after the 
injection.
Ergometrine maleate, dissolved in saline, was injected intraperitoneally in doses 
of 5.0 and 10.0 mg/kg or intravenously (tail vein) in doses of 1.0, 2.0 and 5.0 mg/kg, 
either alone or followed by apomorphine HC1 in a dose of 1.0 mg/kg i.p. about 
20 min later.
Injections directly into the brain
Male Wistar rats were used, weighing 200-220 g at the time o f operation. Under 
sodium pentobarbital anaesthesia (40 mg/kg i.p.) double barrelled stainless steel 
cannulae were implanted bilaterally into different regions of the brain. The injection 
sites aimed for were: the head of the caudaté nucleus in 4 rats (coordinates A 9.4, 
L 2.0, H 1.0 according to the atlas of König and Klippel16); the nucleus accumbens in 
6 rats (coordinates A 9.4, L 1.2, H — 0.6) and the septum in 3 rats (coordinates A 8.0, 
L 0.5, H 0.6). The cannulae placed in the caudate nucleus and the nucleus accumbens 
were brought in from the lateral side at an angle of 10° in order to avoid the ventricles, 
and were fixed on to the skull with acrylic dental cement (Paladur). The cannulae 
placed in the septum were brought in from the cóntralateral side at an angle of 12.5° 
and also at an angle of 12.5° from the posterior and anterior sides. Two jeweller’s 
screws were placed into the skull to firmly attach the cement. The diameter of the 
outer and inner cannulae were 0.65 and 0.30 mm respectively.
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After surgery the animals were put into individual home cages. After a period 
of 2 weeks, in which the animals recovered from the operation and during which time 
they were accustomed to handling, the rats were put into the activity cages several 
times in order to adapt to the new environment.
Injections were given to the unanaesthetized animals by means of a 5 [i\ Hamil- 
ton syringe with a 31-gauge needle, which extended into the brain tissue 1.5-2.0 mm 
below the tip of the permanently embedded cannula. The rats were injected bilaterally 
and unilaterally. The injection volume was always 0.5 fil. Ergometrine maleate, dis- 
solved in saline, was given in doses of 5.0, 2.0, 1.0, 0.5, 0.1 and 0.01 [Jg  on each side. 
After replacement of the inner cannulae the animals were placed singly in semicircular 
cages to observe their behaviour or into a motor activity cage, where their locomotor 
activity was recorded for up to 6 h  or longer if necessary. Following the injection the 
animals were left to recover for at least 2 days before they were used again.
In  some experiments the animals were pretreated with neuroleptics before the 
intracerebral injection of ergometrine. For this purpose haloperidol, dissolved in pro- 
pylene glycol, was given intraperitoneally in doses of 0.1 and 0.5 mg/kg 15 and 30 min 
respectively before the injection of ergometrine. Pimozide, dissolved in diluted l(+ )-  
tartaric acid, was injected intraperitoneally in a dose of 0.1 mg/kg 3 h before ergo­
metrine.
The ty r o s in e  h y d r o x y la s e  i n h ib i to r  D L -a -m e th y l-p - ty ro s in e ,  e m u ls if ie d  w i th  t r a -  
g a c a n th ,  w a s  a d m in i s te r e d  o r a l ly  in  a  d o s e  o f  2 0 0  m g /k g  8 h b e f o re  th e  in je c t io n  o f  
e rg o m e tr in e .
Apparatus
Locomotor activity was measured in activity cages, equipped with 3 light sources 
and opposite to them 3 photoelectric cells 2 cm above the floor. The dimensions of 
the cage were 36 cm X 24 cm x  25 cm. The light beams were arranged in such a 
manner, that one was directed perpendicular to the 2 others and the floor of the cage 
was divided into 6 squares of 12 cm x  12 cm. The cages were situated in a ventilated 
soundproof box and illuminated with a house light of constant intensity. The inter- 
ruptions of the light beams were registered on a cumulative Ralph-Gerbrands re­
corder. After 500 interruptions the pen of the recorder retumed automatically to the 
base line.
Histological procedures
After the end of the experiments the animals were perfused first with saline and 
then with 30 ml of a 10 % formalin solution through the left cardiac ventricle under 
sodium pentobarbital anaesthesia. The brains were removed and kept in a 4 % formalin 
solution for 7 days. After that time the brains were dehydrated and embedded in 
parafHn. Serial 15 [xm thick frontal sections were cut and stained with haematoxylin- 
eosin. The position of the tips of the needle-tracks were marked on a diagram (see 
Fig. 1).
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Fig. 1. Frontal sections of the rat brain according to the atlas of König and Klippel16 in which the 
sites o f application of ergometrine have been indicated. The numbers 1-6 refer to the rats with 
cannulae in the nucleus accumbens; the numbers 7-10 to  rats with cannulae in the caudate nucleus. 
Abbreviations: a, nucleus accumbens; cp, nucleus caudatus putamen; sl, nucleus septalis lateralis.
RESULTS
Intraperitoneal and intravenous injections
Ergometrine injected intraperitoneally (5.0 or 10.0 mg/kg) produced a charac- 
teristic response about 5-10 min after the injection. There was piloerection and the 
rats adopted a characteristic posture. The rats would crawl slowly round the perimeter 
of the cage with the belly touching the floor and the legs (especially the hind legs) 
extended. The movement was irregular and the rats would frequently stay motionless 
for several seconds before moving on again. When provoked by a sound stimulus the 
rats would temporarily adopt a normal running posture. The effect of ergometrine 
on the posture of the animal normally began to wear off about 60-90 min after the 
injection. In all cases the animals recovered and looked normal the following day.
A similar effect was observed after the intravenous injection of ergometrine (1.0, 
2.0 or 5.0 mg/kg); in these experiments the effect came on within 1 min of the injection 
and lasted for about 20-60 min.
When animals treated with ergometrine intraperitoneally or intravenously were 
studied in an activity cage, there was no sign of a strong effect on locomotor activity 
(see Fig. 3B).
In some experiments, animals which had received ergometrine (5.0 or 10.0 mg/kg 
i.p.) were then injected after about 20 min with apomorphine (1.0 mg/kg i.p.). The 
effect of the ergometrine was reversed within 5 min and the animals now showed a 
strong behavioural response to apomorphine, including compulsive gnawing, arching 
of the back, Straub tail’s phenomenon and sometimes the bizarre behaviour described 
by Lammers and van Rossum17. In some cases, especially with the higher doses of 
ergometrine, the combination of ergometrine followed by apomorphine was fatal; in
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Fig. 2. M otor activity of a  ra t (rat 1) as measured in the activity cage. After a  period of adaptation 
to  the cage, ergometrine 2.0 jig bilaterally is injected into the nucleus accumbens (black arrow). 
Following the injection there is a  period of low activity. After about 1 h the motor activity increases 
and remains at a high constant level for several hours.
these animals there were circling movements, much tail-biting and convulsions with 
death, occurring about 30-60 min after the injection of apomorphine.
Intracerebral injections
Bilateral injections. After bilateral injection of different doses of ergometrine 
into the nucleus accumbens there was a biphasic response. Within a few minutes after 
the injection the animals showed ptosis and sedation. Further, the animals showed 
signs of shivering, abortive grooming, scratching the body and involuntary movements 
of the legs, the trunk and the head. In  a few cases the characteristic crawling move­
ments as seen after intraperitoneal or intravenous injection appeared after intra­
cerebral injection. After a period of 30-60 min following the injection the animals 
began to run and showed a strong locomotor activity. This enhanced locomotor activ­
ity started in most cases very suddenly and lasted for up to 7 or 8 h after the injection 
of 5.0 fJig. Fig. 2 shows the effect of injection of 2.0 fig bilaterally as measured in the 
activity cage. This phenomenon was observed in all 6 rats with cannulae embedded
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Interruptions/5 min
Fig. 3. A : shows the time course o f locomotor activity of a rat (rat 5) after injection o f 2.0 fig bi- 
laterally into the nucleus accumbens. In  this and the following figures the values for m otor activity, 
as calculated from the cumulative recording data, are averaged over 5 min periods and plotted. 
B : shows the motor activity of a rat following the injection of ergometrine 10 mg/kg intraperitoneally.
in the nucleus accumbens. The same rats injected with ergometrine 2 or more days 
later showed a similar locomotor stimulation. The injection of saline (0.5 [A bilater- 
ally) had no effect on the m otor activity (see Fig. 4A). When ergometrine was injected 
into the caudate nucleus the animals also showed ptosis and sedation, and the same 
signs of shivering, abortive grooming and so on were observed. However, relative to 
the effect seen after injection into the nucleus accumbens, there was only a slight
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Fig. 4. A : m otor activity (averaged/5 min) of a  ra t (rat 4) after the injection of 0.5 jA saline bilaterally 
into the nucleus accumbens. B: motor activity (averaged/5 min) o f a ra t (rat 10) after the injection 
of 5.0 fi% ergometrine bilaterally into the caudate nucleus. C: for comparison the motor activity of 
a  ra t is shown following the injection of D-amphetamine sulphate 1.5 mg/kg i.p.
enhancement of motor activity starting about 90 m in after the injection of 5.0 fig 
bilaterally and usually lasting for up to 3-4 h  (see Fig. 4B).
Injection into the septum (2.0 /j,g bilaterally) had no stimulant effect on loco- 
m otor activity.
Ergometrine in lower doses (1.0 and 0.5 fj,g bilaterally) when injected into the 
nucleus accumbens again produced enhanced locomotor activity in all 6 animals. 
However, at these dose levels, although the m otor activity, when measured and aver- 
aged over 5 min periods, was approximately as high as with a dose of 5.0 fig bilater­
ally, the duration of the effect was shorter. Thus after the administration of 1.0 //g 
the m otor activity lasted for about 4-5 h. After the injection of 0.5 fig, locomotor 
activity was increased for about 3-4 h. W ith even lower doses of ergometrine injected 
into the nucleus accumbens fewer animals responded. After doses of 0.1 fig bilaterally
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there was locomotor stimulation in only 3 out of 6 animals. In the animals that did 
respond the locomotor stimulation lasted for about 2-3 h. Ergometrine 0.01 fxg was 
only effective in 1 out of 6 animals which showed locomotor stimulation lasting for
2 h.
When injected into the caudate nucleus in doses of 1.0 fig or 0.5 [ig bilaterally, 
ergometrine was without stimulant effect on locomotor activity.
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Fig. 5. A : m otor activity of a ra t (rat 3) following the injection of ergometrine 1.0 bilaterally into 
the nucleus accumbens. B: m otor activity o f the same rat, pretreated with pimozide 0.1 mg/kg i.p.,
3 h  before the injection of ergometrine. The locomotor stimulation is strongly inhibited. A bout 3 h  
after the injection of ergometrine there is a slight stimulation of locomotor activity lasting for about
1 h.
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In most cases the enhanced locomotor activity induced by injection of ergo­
metrine into the nucleus accumbens started rather abruptly and remained continu-
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Fig. 6. A : m otor activity of a rat (rat 6) following the injection of 0.5 /.tg ergometrine bilaterally into 
the nucleus accumbens. B: motor activity of the same ra t after pretreatment with haloperidol 0.1 
mg/kg i.p. 15 min before the injection of ergometrine. The locomotor stimulation is completely 
inhibited.
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ously high for long periods. The cessation of activity was rather sudden and was 
usually preceded by short pauses. It should be noted that during this period of strong 
locomotor activity the animals showed no sign of aggressiveness but, on the contrary, 
could be handled very easily without resistance. When they were handled, they stopped 
their activity and after they had been replaced in the observation cage they resumed 
their running. The motor activity consisted of coordinated movements. The animals 
continuously showed walking, running, rearing or climbing and could easily avoid 
obstacles. When the rats were placed on a table and reached the edge of it, they never 
feil off. During this period of activity very little or no grooming was observed.
Pimozide (0.1 mg/kg i.p.) given 3 h  before the injection of ergometrine (1.0 fxg 
bilaterally) into the nucleus accumbens completely blocked the locomotor stimulant 
effect in 3 out of 6 rats. In 2 other rats, pretreated with this dose of pimozide, ergo-
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Fig. 7. M otor activity of a ra t (rat 2) following the injection of ergometrine 1.0 fig bilaterally into the 
nucleus accumbens after pretreatment with a-methyl-p-tyrosine 200 mg/kg orally 8 h  before the 
injection o f ergometrine.
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metrine produced only a slight enhancement of locomotor activity which started after
3 and 3.5 h  respectively and which lasted for only 1 h (see Fig. 5). In the remaining 
ra t there was no sign of inhibition of the ergometrine effect by pimozide.
Haloperidol (0.1 mg/kg i.p.), when given 15 min before, completely antagonized 
the locomotor activity after bilateral injection of 0.5 fig ergometrine in 5 out of 6 rats 
(see Fig. 6). In the remaining rat locomotor stimulation was still produced but only 
after a delay of 100 min. The inhibition by haloperidol was overcome by higher doses 
of ergometrine. The effect of ergometrine, 5.0 fig bilaterally, was inhibited by 0.5 
mg/kg i.p. given 30 min before in only 2 out of 6 rats.
Injection o f  the s o lv e n ts  p r o p y le n e  g ly c o l  o r  L ( - |- ) - t a r ta r ic  acid s o lu t io n  h a d  n o  
e ffe c t  on t h e  e n h a n c e d  activity.
a-Methyl-p-tyrosine (200 mg/kg orally), administered 8 h before the injection 
of ergometrine (1.0 fig bilaterally) into the nucleus accumbens, had no clear-cut 
effect on the locomotor stimulation in any of the 6 rats (see Fig. 7), although the rats 
were strongly sedated before they received ergometrine.
Unilateral injections. After unilateral injection of 5.0 fig ergometrine into the 
nucleus accumbens the animals showed the same phenomena as after bilateral injec­
tions. After a period of 30-60 min they became active. The duration of this activity 
was less than after bilateral injection, lasting for 3-4 h. Also the degree of activity 
was considerably less (see Fig. 8). When the animals started to run they often showed 
turning to the contralateral side (opposite to the side injected). In some animals there 
was only a slight preference for contralateral turning, in other animals this turning 
was very apparent and they turned 10-15 times/min. This contralateral turning was 
also observed, although to a lesser degree, after unilateral injection of 5.0 fig ergo­
metrine into the caudate nucleus. In most cases this turning behavior was of shorter 
duration than the activity period.
Fig. 8. M otor activity of a rat (rat 6) following the injection of ergometrine 5.0 fig unilaterally (left 
side).
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DISCUSSION
The crawling behaviour induced by intraperitoneal injection of ergometrine in 
rats is similar to the phenomenon in rabbits and cats reported by Brown and Dale5, 
who concluded that this effect was mediated by a central mechanism.
A surprising finding in our study was the strong locomotor stimulation following 
the injection of small amounts of ergometrine into the nucleus accumbens. When 
injected intraperitoneally or intravenously ergometrine had no such effect. It is pos- 
sible that ergometrine does not reach the nucleus accumbens in sufficiënt concentra- 
tion following peripheral administration. Alternatively, it is likely that following intra­
peritoneal or intravenous injection any effect of ergometrine on the nucleus accumbens 
can be inhibited or modified by an action of ergometrine on other areas of the brain. 
Our results suggest that the nucleus accumbens might be important in controlling 
locomotor activity.
The nucleus accumbens contains a high density of dopamine nerve terminals. 
This nucleus takes part of the so called mesolimbic dopamine system2’3’20. Axons of 
dopamine cell-bodies dorsocranial to the interpeduncular nucleus in the ventral 
mesencephalon (Aio-group according to Dahlström and Fuxe10) ascend together 
with axons of the nigrostriatal dopamine system, but follow a more medial route. 
The nerve terminals of these axons enter the nucleus accumbens, the nucleus inter- 
stitialis striae terminalis and the tuberculum olfactorium2>3’12'20.
Little is known about the functional role of this dopamine system. Crow9 has 
shown that electrical self-stimulation can be elicited by electrodes in the Aio-cell 
group. Also the nucleus accumbens is known to be a site for self-stimulation18. In 
contrast to medial forebrain bundle self-stimulation, which influences the activity of 
many brain stem units and causes arousal, stimulation in the nucleus accumbens 
influences only very few brain stem units and causes hypoactivity18. Therefore it is 
difficult to explain the strong locomotor activity after ergometrine injections into 
the nucleus accumbens by an influence on the brain stem reticular formation.
A remarkable fact is the long latency time with regard to the locomotor stimula­
tion. Usually there is a delay of 30-60 min after the injections before the animals 
start to run. One possibility is that diffusion must take place to a site where the ergo­
metrine is acting. However, the injection of ergometrine into surrounding structures 
such as the caudate nucleus and the septum had little or no effect on the locomotor 
activity. Moreover, diffusion is dependent on the concentration of the drug; it seemed, 
however, that different concentrations of ergometrine had the same latency time.
Another possibility is that a metabolite of ergometrine is the active component. 
Very little is known about the metabolism of ergometrine and other ergot-alkaloids. 
W ith regard to the rather abrupt start and finish of the locomotor activity and also 
to the fact that the activity remains at a constant high level independent of the concen­
tration, it is most likely that some system must be ‘triggered’. Which system this could 
be is unknown at present. In this respect it is worthy of mention that electrical stimula­
tion of the dorsomedial posterior hypothalamus consistently produced running, rear- 
ing and other ‘voluntary movements’ throughout the stimulation period and that
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these movements were accompanied by rhythmical slow activity in the hippocampus 
as shown by Bland and Van der W olf4.
Ergometrine is a substance, like other ergot-alkaloids, with a rather complex 
mechanism of action. It is known for instance that ergometrine will potentiate the 
action of noradrenaline on the guinea-pig vas deferens preparation24. It is also known 
that ergometrine is a potent antagonist of 5-hydroxytryptamine8. However, methy- 
sergide, another antagonist of 5-hydroxytryptamine, was ineffective in producing 
locomotor stimulation (unpublished observation). As already mentioned in the intro- 
duction, ergometrine inhibits the dopamine response in the snail brain. In the rat, 
ergometrine injected intraperitoneally or intravenously was unable to inhibit the 
behavioural effects of apomorphine.
The locomotor stimulation was blocked by low doses of haloperidol and pimo- 
zide. Haloperidol is a potent antagonist of the stereotyped behaviour induced by 
amphetamine11'22 and also antagonizes the behavioural effects produced by injection 
of dopamine into the caudate nucleus of conscious cats6>7. Haloperidol and pimozide 
in low doses are believed to block dopaminergic receptors in mammals1-15-21’22. It is 
therefore quite possible that dopaminergic receptors are involved in this action of 
ergometrine. A presynaptic action is unlikely, because pretreatment with a-methyl-p- 
tyrosine, which causes a depletion of dopamine and noradrenaline in the brain19, had 
no influence. However, other mechanisms of action cannot be ruled out.
Further experiments to elucidate the mode by which ergometrine causes this 
strong and long-lasting motor activity are in progress.
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